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leeding Among Patients Admitted With
yocardial Infarction
Report From the NCDR ACTION Registry–GWTG (National Cardiovascular
ata Registry Acute Coronary Treatment and Intervention
utcomes Network Registry–Get With the Guidelines)
itul B. Kadakia, MD,*† Nihar R. Desai, MD, MPH,*† Karen P. Alexander, MD,‡
nita Y. Chen, MS,‡ JoAnne M. Foody, MD,† Christopher P. Cannon, MD,*†
tephen D. Wiviott, MD,*† Benjamin M. Scirica, MD, MPH,*† on behalf of the
ational Cardiovascular Data Registry
oston, Massachusetts; and Durham, North Carolina
bjectives The aim of this study was to evaluate anticoagulant use patterns and bleeding risk in a
ontemporary population of patients with acute coronary syndrome.
ackground Current practice guidelines support the use of unfractionated heparin, low molecular
eight heparin, bivalirudin, or fondaparinux in non–ST-segment elevation myocardial infarction
NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Little is known about how these
gents are selected in clinical practice.
ethods Between January 2007 and June 2009, data were captured for 72,699 patients with
STEMI and 48,943 patients with STEMI at 360 U.S. hospitals for the NCDR ACTION Registry–GWTG
National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Net-
ork Registry–Get With the Guidelines). Patients were categorized based on anticoagulant strategy
elected during hospitalization and their CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
atients Suppress Adverse Outcomes With Early Implementation of ACC/AHA [American College of
ardiology/American Heart Association] Guidelines) bleeding risk category.
esults At least 1 anticoagulant was administered to 66,279 patients (91.2%) with NSTEMI and
6,149 patients (94.3%) with STEMI. Among STEMI patients, unfractionated heparin was most com-
only used (66%), followed by bivalirudin (14%) and low molecular weight heparin (8%). In NSTEMI
atients, unfractionated heparin was also the most commonly used anticoagulant (42%), followed
y low molecular weight heparin (27%) and then bivalirudin (13%). There were signiﬁcant differ-
nces in anticoagulant use by age, risk factors, concomitant medications, and invasive care. There
as a 5-fold difference in the rate of bleeding between patients in the lowest and highest CRUSADE
leeding risk groups, which was consistently observed in most anticoagulant groups.
onclusions There is a wide variability in the use of anticoagulant regimens with signiﬁcant differ-
nces according to baseline characteristics and concomitant therapies. Major bleeding is common,
hough a great degree of the variability in the rate of bleeding is largely based on differences in
aseline characteristics, comorbidities, and invasive treatment strategies, rather than speciﬁc antico-
gulant regimens. (J Am Coll Cardiol Intv 2010;3:1166–77) © 2010 by the American College of
ardiology Foundation
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1167ubstantial clinical trial experience has compared different
nticoagulant regimens in patients with ST-segment eleva-
ion myocardial infarction (STEMI) (1–3) and non–ST-
egment elevation acute coronary syndrome (ACS) (4–8),
et relatively little is known about the current use of
vailable agents in clinical practice. Anticoagulant therapy
emains a cornerstone of management of ACS and is
ndorsed by practice guidelines for STEMI and unstable
ngina/non-STEMI (NSTEMI) (9–12). Based primarily
n clinical trial results, unfractionated heparin (UFH), low
olecular weight heparin (LMWH), fondaparinux, and
ivalirudin have all received the highest guideline recom-
endations in various clinical presentations of ACS (9–12).
ompared with the general population, subjects in clinical
rials are younger and by design have fewer of the comor-
idities that increase their risk of complications of antico-
gulant therapy, including bleeding. Thus, greater appreci-
tion of real-world practice patterns of anticoagulant
See page 1178
herapy and the associated risk of bleeding is important in
nderstanding the circumstances and consequences of their
se. We sought to examine the use of available anticoagu-
ant agents across the spectrum of patients admitted with
yocardial infarction in a contemporary cohort of over
21,000 patients in the NCDR ACTION Registry–
WTG (National Cardiovascular Data Registry Acute
oronary Treatment and Intervention Outcomes Network
egistry–Get With the Guidelines).
ethods
CTION Registry–GWTG. The ACTION registry is a quality
mprovement registry of patients with myocardial infarction
n the U.S. Participating sites enroll consecutive patients;
herefore, it is an unselected population. Eligibility included
atients with STEMI and NSTEMI. STEMI and
STEMI are defined for registry inclusion by: 1) ischemic
ymptoms at rest, lasting 10 min, occurring within 24 h
efore admission or up to 72 h for STEMI; 2) electrocar-
rom the *TIMI Study Group, Brigham and Women’s Hospital and Harvard
edical School, Boston, Massachusetts; †Cardiovascular Division, Brigham and
omen’s Hospital and Harvard Medical School, Boston, Massachusetts; and ‡Duke
linical Research, Institute and Division of Cardiology, Duke University Medical
enter, Durham, North Carolina. The NCDR ACTION Registry–GWTG is admin-
stered by the American College of Cardiology Foundation (ACCF) and sponsored by
ristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Genentech, and Schering-Plough
orporation, who provide material support for the operation of the data collection and
nfrastructure. The sponsors had no additional role in this project including the selection of
opic, analysis of data, decision to publish, or approval of the manuscript before publication. Dr.
oody reports receiving consulting fees from Bristol-Myers Squibb, Merck, Pfizer, and
anofi-Aventis. Dr. Cannon reports receiving research grants from Accumetrics, AstraZeneca,
laxoSmithKline, Intekrin Therapeutics, Merck, and Takeda; he is a clinical adviser for and
olds equity in Automedics Medical Systems; he is on the Advisory Board (but funds Miogram changes associated with STEMI (new left bundle-
ranch block or persistent ST-segment elevation 1 mm
n 2 or more contiguous electrocardiographic leads); or
) positive cardiac markers associated with NSTEMI (cre-
tine kinase-MB isoenzyme or troponin I/T  local labo-
atory upper limit of normal values) within 24 h after initial
resentation. Patients are ineligible for the ACTION reg-
stry if they develop ischemic symptoms that meet the
iagnostic criteria for STEMI and NSTEMI during hos-
italization but were originally admitted for clinical condi-
ions unrelated to STEMI and NSTEMI diagnosis (13).
Hospitals in this registry are diverse in size, teaching
tatus, capacity, and region. Participating hospitals collect
ata through retrospective chart review using standardized
ata collection tools that do not require direct contact with
ndividual patients. Data collected include patient demo-
raphics, presenting features, pre-hospital therapy, in-
ospital therapy, hospital discharge therapy, timing of care
elivery, laboratory tests, proce-
ure use, and in-hospital patient
utcomes. The Institutional Re-
iew Board of each hospital ap-
roved its organization’s partici-
ation in the registry (13).
The population included 51,980
atients with STEMI and 80,000
atients with NSTEMI enrolled
t 360 U.S. hospitals from January
007 to June 2009. Patients were
xcluded sequentially if they had a
ontraindication to receiving an
nticoagulant agent or if the agent
dministered was blinded (n 
62 in STEMI, n  3,390 in
STEMI) and if anticoagulant
gent used was missing or was not
aptured on the data collection instrument (n  2,112 in
TEMI, n  3,624 in NSTEMI). Furthermore, due to the
ery infrequent use of fondaparinux, these patients were also
xcluded (n  163 [0.3%] for STEMI, n  287 [0.4%] for
STEMI). The remaining study population includes 48,943
atients with STEMI and 72,699 patients with NSTEMI.
onated to charity) for Bristol-Myers Squibb/Sanofi, Novartis, and Alnylam; and he received
onorarium for development of independent educational symposia: Pfizer, AstraZeneca. Dr.
iviott reports receiving honoraria for educational presentations from Bristol-Myers Squibb,
aiichi Sankyo, Eli Lilly, Schering-Plough, Merck, and The Medicines Company; consulting
ees from AstraZeneca, Bristol-Myers Squibb, and Sanofi-Aventis; and research grant support
rom Daiichi Sankyo, Eli Lilly, and Schering-Plough. Dr. Scirica has received honoraria for
ducational presentations from CV Therapeutics, Merck, Novartis, and Schering-Plough;
onsulting fees from AstraZeneca, Cogentus, and Novartis; and received research grant
upport from AstraZeneca, Bristol-Myers Squibb, CV Therapeutics, Merck, Daiichi Sankyo,
ovartis, Johnson & Johnson, and Bayer Healthcare, as well as an unrestricted research grant
rom the Michael Lerner Foundation. All other authors have reported that they have no
elationships to disclose.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
GP  glycoprotein
LMWH  low molecular
weight heparin
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
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1168For the major bleeding analysis, patients were also ex-
luded sequentially if they were transferred to another
acility as data were unavailable for non-ACTION hospitals
n  8,172); were on home warfarin (n  5,504); had a
aseline hematocrit recorded after a lowest hematocrit (n 
74); had a baseline hematocrit recorded after a packed red
lood cell transfusion (n  18); had missing major bleeding
ata (n  47); had missing age, sex, and/or race (n 
,174); or if they died within 48 h of presentation (n 
,795). There were 42,918 STEMI and 61,540 NSTEMI
atients in the final analysis set.
eﬁnitions. Creatinine clearance was estimated with the
ockroft-Gault formula and was derived from data on
dmission, before any procedures (14). Major bleeding
as determined if an event met 1 of the following criteria:
) absolute hematocrit drop of 12%; 2) intracranial hem-
rrhage; 3) retroperitoneal bleeding; 4) red blood cell
ransfusion if baseline hematocrit  28%; or 5) red blood
ell transfusion if baseline hematocrit 28% with report
f a witnessed bleeding event. For patients undergoing
urgical revascularization, criteria for bleeding had to
ccur before coronary artery bypass graft surgery. A
isting of specific data fields and additional definitions are
vailable on NCDR’s website (15).
tatistical analysis. STEMI and NSTEMI were analyzed
eparately. Patients were then divided into 5 groups based
n anticoagulant strategy used during hospitalization: 1) no
nticoagulant therapy; 2) UFH alone; 3) LMWH alone;
) both UFH and LMWH; or 5) any bivalirudin (alone or
n combination with other anticoagulant therapies) (Fig. 1).
ivalirudin patients were further divided based on whether
hey received bivalirudin alone or in combination with other
nticoagulant therapies. Baseline patient demographics,
edical history, presentation features, and concomitant
herapies were examined across the treatment groups. Me-
ian values with interquartile ranges (IQR: 25th, 75th
ercentiles) were used to describe continuous variables, and
umbers (percentages) were reported for categorical vari-
bles. Continuous and ordinal categorical variables were
ompared using the stratum adjusted Wilcoxon rank-sum
est (2 samples) and Kruskal-Wallis test (more than 2
amples), whereas nominal categorical variables were com-
ared using the stratum adjusted chi-square test where
tratification is by hospital. Furthermore, selection of pa-
ients on each anticoagulant therapy was explored according
o therapeutic strategy (e.g., primary percutaneous coronary
ntervention [PCI] and fibrinolytics for STEMI, and inva-
ive and conservative strategy for NSTEMI). Finally, use of
nticoagulants was also divided by quarter to examine time
rends in usage.
To evaluate the risk of bleeding observed in the different
nticoagulant strategies, we used the CRUSADE (Can
apid Risk Stratification of Unstable Angina Patients suppress Adverse Outcomes With Early Implementation of
CC/AHA [American College of Cardiology/American
eart Association] Guidelines) bleeding risk score to ac-
ount for patient-specific variables known at baseline to
ffect bleeding rates. The construction of this score has
reviously been described and validated (16). Briefly, the
RUSADE bleeding risk score assigns points based on
criteria: 1) baseline hematocrit; 2) creatinine clearance;
) heart rate; 4) sex; 5) signs of congestive heart failure;
) systolic blood pressure; 7) prior vascular disease (prior
troke or peripheral artery disease); and 8) diabetes
ellitus. Age is not included separately in this model as
t is a component of the Cockroft-Gault formula for
stimating creatinine clearance. In the original derivation
nd validation of the risk score, it did not remain a
ignificant covariate in the model in the presence of other
ovariates and, therefore, was not included in the final
odel (16). Patients were divided into 5 groups based on
he CRUSADE bleeding risk score (20, 21 to 30, 31 to
0, 41 to 50, and 50) (Fig. 1). Overall rates of major
leeding and were presented across the CRUSADE
leeding risk score categories for STEMI and NSTEMI.
n addition, the distribution of the CRUSADE bleeding risk
Figure 1. Flow of Subjects Included in Analysis From the ACTION
Registry–GWTG and Definitions of CRUSADE Bleeding Risk Score
Anticoagulant strategy and CRUSADE bleeding risk score were used to
categorize 121,642 patients with ST-segment elevation myocardial infarc-
tion (STEMI) or non–ST-segment elevation myocardial infarction (NSTEMI).
ACTION  Acute Coronary Treatment and Intervention Outcomes Network;
CHF  congestive heart failure; CrCl  creatinine clearance (determined
with Cockroft-Gault formula); CRUSADE  Can Rapid Risk Stratiﬁcation of
Unstable Angina Patients Suppress Adverse Outcomes With Early Imple-
mentation of ACC/AHA [American College of Cardiology/American Heart
Association] Guidelines; DM2  diabetes mellitus type 2; GWTG  Get With
the Guidelines; Hct  hematocrit; HR  heart rate; LMWH  low molecular
weight heparin; SBP  systolic blood pressure; UFH  unfractionated
heparin.core categories by anticoagulant strategies was displayed in
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1169atients with STEMI and NSTEMI. A graphical presentation
f unadjusted rates of major bleeding according to anticoagu-
ant and the CRUSADE bleeding risk score category was
hown in patients with STEMI and NSTEMI. Rates of
leeding in STEMI by the CRUSADE bleeding risk score
ategory were further stratified based on reperfusion strategy
nd use of anticoagulant strategies. Lastly, usage trends during
his period (January 2007 to June 2009) were explored.
A p value of0.05 was considered statistically significant
or all tests. All analyses were performed using SAS software
version 9.2, SAS Institute, Cary, North Carolina).
esults
verall anticoagulant use. Among STEMI patients, UFH
as the most commonly used anticoagulant agent (66%)
ollowed by bivalirudin (14%) and LMWH (8%). In
STEMI patients, UFH was also the most commonly
sed anticoagulant (42%) though there was a relative
reater use of LMWH (27%) and bivalirudin (13%)
Figs. 2A and 2B).
TEMI. Among the STEMI cohort, there were significant
ifferences in baseline demographics between patients in
ach of the different anticoagulant groups (Table 1). In
he STEMI cohort, patients who received LMWH were
ore likely to be 75 years of age, women, and have
educed renal function (estimated glomerular filtration
ate 60 ml/min) than patients receiving either UFH or
ivalirudin.
Concomitant use of a glycoprotein (GP) IIb/IIIa inhib-
tor was more frequent in patients receiving UFH (79.1%)
nd LMWH (61.8%), though almost one-half (44.5%) of
atients treated with bivalirudin also received a GP IIb/IIIa
nhibitor (p  0.0001). Concomitant use of clopidogrel was
ore frequent in patients receiving bivalirudin (94.5%) than
atients receiving UFH (88.0%) or LMWH (73.7%) (p 
.0001). Fibrinolytics were most commonly used alongside
MWH (27.9%) as opposed to UFH (11.6%) or bivalirudin
9.7%) (p  0.0001). However, fewer patients receiving
MWH had primary PCI (58.0%) than patients receiving
FH (81.8%) and bivalirudin (83.9%) (p  0.0001)
Table 1). In patients who received bivalirudin, there were
ignificant differences in reperfusion strategy based on
hether the patient received bivalirudin alone or in
ombination with other agents. Of patients who received
ivalirudin alone, 92.7% underwent primary PCI versus
9.3% of patients who received bivalirudin in combina-
ion with other agents. In contrast, only 2.5% of patients
ho received bivalirudin alone underwent fibrinolytic
herapy versus 13.5% of patients who received bivalirudin
n combination with other agents (Online Appendix,nline Table 1A). Lnticoagulant in STEMI according to reperfusion strategy.
mong patients undergoing primary PCI only (n 32,544,
9.9% of eligible STEMI patients without contraindica-
ions to reperfusion), UFH was the most commonly used
nticoagulant (68.3%), followed by bivalirudin (16.8%), no
nticoagulant agent (5.1%), both UFH and LMWH
5.0%), and LMWH (4.8%). In patients receiving a fibrino-
ytic (n  5,123, 12.6% of eligible STEMI patients without
ontraindications to reperfusion), UFH was also the most
ommonly used agent (61.6%), followed by LMWH
14.5%), bivalirudin (12.3%), and both UFH and LMWH
9.2%) (Fig. 3).
STEMI. In the NSTEMI cohort, patients receiving
Figure 2. Usage of Anticoagulant Regimens in STEMI and NSTEMI Patients
The usage of each of the 5 anticoagulant strategies is presented in
STEMI (A) and NSTEMI (B) patients. Abbreviations as in Figure 1.MWH were more likely to be elderly, women, or have
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1170mpaired renal function than those patients receiving
FH or bivalirudin. Concomitant pharmacologic and
nvasive therapies also varied between groups. Those
eceiving bivalirudin were less likely to be simultaneously
reated with a GP IIb/IIIa inhibitor (23.8%) than pa-
ients receiving UFH (51.4%) or LMWH (37.3%) (p 
.0001). Clopidogrel was used more frequently in the
ivalirudin group (76.7%) than the UFH (62.0%) and
MWH (51.2%) groups (p  0.0001) (Table 2). In
atients who received bivalirudin, there were no clinically
ignificant differences between those who received biva-
irudin alone or in combination with other agents (Online
ppendix, Online Table 1B).
nticoagulant use according to invasive versus conservative
trategy. Among patients undergoing an invasive strategy
ith cardiac catheterization with or without PCI in the first
8 h after admission (n  46,012, 74.2% of eligible
STEMI patients without contraindications to cardiac
atheterization), UFH was the most commonly used anti-
oagulant agent (46.0%), followed by LMWH (20.8%),
ivalirudin (16.8%), and both UFH and LMWH (10.5%).
Table 1. Baseline Characteristics and Concomitant Therapies by Anticoagu
Overall None
Patients, n 48,943 2,794
Baseline characteristics
Age 75 yrs, % 19.1 23.3
Men, % 70.0 65.5
Diabetes mellitus, % 22.4 23.7
Prior vascular disease, % 9.5 11.7
Signs of CHF, % 11.6 14.9
Heart rate, beats/min* 78 (65–92) 79 (66–94)
SBP, mm Hg* 139 (118–159) 137 (117–159)
BMI, kg/m2* 28.1 (25.0–32.0) 27.8 (24.5–31.6)
Baseline hematocrit, % 42.9 (39.2–46.2) 42.0 (38.0–45.4)
eGFR, ml/min/1.73 m2*† 85.5 (61.4–112.1) 81.8 (55.8–110.5)
eGFR 60 ml/min/1.73 m2, %† 23.6 28.2
Concomitant therapies, %
Clopidogrel‡ 86.8 75.0
75 mg 9.6 16.6
150 mg 0.9 0.9
300 mg 29.6 27.0
600 mg 57.8 53.0
Other 1.0 1.0
GP IIb/IIIa inhibitor 71.5 62.9
No reperfusion 6.1 10.5
Fibrinolytic only 12.6 6.3
Primary PCI only 79.9 82.0
*Continuous variables displayed as median values with 25th, 75th percentiles. †eGFR determined
was missing for a small percentage of patients, thus the percentage of distribution by dose does no
BMIbodymass index; CHF congestive heart failure; eGFR estimated glomerular filtration ra
SBP systolic blood pressure; STEMI ST-segment elevation myocardial infarction; UFH unfracn patients treated with a conservative strategy without pardiac catheterization or cardiac catheterization after the
rst 48 h of admission (n  15,631, 25.2% of eligible
STEMI patients without contraindications to cardiac
atheterization), LMWH was the most commonly used
nticoagulant (35.0%) followed by UFH (34.6%), bivaliru-
in (9.4%), and both LMWH and UFH (9.2%) (Fig. 3).
ime trends in anticoagulant use. Anticoagulant use was
lso examined over time, by quarter, from January 2007 to
une 2009. In STEMI, bivalirudin use has risen from 10.2%
o 20.9%, whereas UFH alone and LMWH alone have
ropped (66.9% to 62.3% and 11.1% to 5.9%, respectively).
n NSTEMI, bivalirudin use has increased from 10.2% to
6.5%, whereas LMWH alone has dropped from 30.8% to
3.4%. Use of UFH alone has remained stable at approxi-
ately 40% (Figs. 4A and 4B).
ajor bleeding. More than 50% of patients with either
TEMI or NSTEMI were in the 2 lowest (20 or 21 to
0) of the 5 CRUSADE bleeding risk groups. More
STEMI patients (33.7%), compared with only 17.3% of
TEMI patients, were in the highest 2 risk groups (41 to
0 or 50) (Table 2). This was due to the NSTEMI
gent: STEMI Patients
UFH LMWH UFH  LMWH Bivalirudin
32,214 4,044 2,946 6,945
18.2 23.7 21.5 18.4
70.9 67.3 67.0 70.5
22.0 24.7 23.9 22.0
8.9 11.3 10.8 9.6
10.9 15.6 16.6 9.5
(65–92) 79 (66.5–95) 80 (66–96) 78 (65–92)
(118–159) 138 (117–158) 137 (117–158) 140 (119–159)
(25.1–32.0) 28.0 (24.8–32.2) 28.0 (24.8–32.0) 28.3 (25.2–32.1)
(39.3–46.2) 42.6 (38.7–46.0) 42.5 (38.7–45.7) 42.9 (39.3–46.2)
(62.5–112.5) 81.2 (55.8–108.8) 79.8 (56.9–106.8) 87.3 (62.9–114.6)
22.5 28.4 27.9 22.1
88.0 73.7 84.6 94.5
8.6 17.9 12.4 7.1
0.9 1.2 1.8 0.7
29.9 34.0 36.1 24.9
58.6 45.2 47.6 65.3
1.0 0.6 1.1 1.2
79.1 61.8 72.4 44.5
5.3 12.2 8.4 5.0
11.6 27.9 20.1 9.7
81.8 58.0 69.5 83.9
ckroft-Gault formula; dialysis patients excluded from calculations. ‡Clopidogrel dose information
100%.
glycoprotein; LMWH lowmolecular weight heparin; PCIpercutaneous coronary intervention;
heparin.lant A
78
139
28.1
43.0
86.3
with Co
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te; GPopulation having a greater proportion of subjects who
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1171ere women (38.5% in NSTEMI vs. 30% in STEMI)
nd with more comorbidities including diabetes mellitus
34.1% in NSTEMI vs. 22.4% in STEMI), prior vascular
isease (18.6% in NSTEMI vs. 9.5% in STEMI), esti-
ated glomerular filtration rate 60 (36.5% in STEMI
s. 23.6% in STEMI), signs of congestive heart failure
20.4% vs. 11.6% in STEMI) than the STEMI popula-
ion. Despite their overall lower risk profile, patients with
TEMI had higher rates of bleeding than those with
STEMI across all the CRUSADE bleeding risk groups
Table 3).
The distribution of the CRUSADE bleeding risk
roups among each anticoagulant group is presented in
igures 5A and 5B. A higher percentage of STEMI
atients in the lowest CRUSADE bleeding risk group
20) received UFH (45.6%) and bivalirudin (45.7%) than
MWH (38.8%). Conversely, a higher percentage of pa-
ients in the highest CRUSADE risk group (50) received
MWH (12.5%) compared with UFH (6.6%) and bivaliru-
in (6.5%). Overall, the greatest variation in anticoagulant
se occurred in the low and high CRUSADE bleeding risk
Figure 3. Anticoagulant Use According to Therapeutic Strategy
Use of anticoagulant by therapeutic strategy in both STEMI and NSTEMI were
Figures 1 and 2.roups. CIn both STEMI and NSTEMI cohorts, there was
oughly a 5-fold difference in the rate of bleeding between
atients in the lowest and highest CRUSADE bleeding risk
roups that was consistently observed in most anticoagulant
roups. A similar gradient of bleeding risk was even ob-
erved among patients who received no anticoagulant ther-
py during their hospitalization (Figs. 6A and 6B).
We further examined the rates of bleeding in STEMI
y CRUSADE bleeding risk score based on reperfu-
ion strategy selected (no reperfusion, fibrinolytics alone,
rimary PCI alone, or both fibrinolytics and PCI) and
se of reperfusion strategies in STEMI based on the
RUSADE bleeding risk score. Among each subgroup,
here is an increased rate of major bleeding events in the higher
RUSADE bleeding risk score categories. There is perhaps
trend toward higher rates of absolute bleeding seen within
he fibrinolytics alone and primary PCI alone groups. There
s a very small sample size of patients who received both
brinolytics and PCI, and it is difficult to make any conclusions
bout this group (Online Appendix, Online Figs. 1A to 1E).
nalysis of the usage of therapeutic strategies based on the
ned. PCI  percutaneous coronary intervention; other abbreviations as inexamiRUSADE bleeding risk score demonstrates that those in the
h
l
t
P
f
s
O
D
I
U
i
m
c
h
c
w
t
c
p
(
a
m
l
b
b
s
a
L
s
N
Y
a
n
L
l
m
U
o
s
t
s
t
T
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 1 , 2 0 1 0
N O V E M B E R 2 0 1 0 : 1 1 6 6 – 7 7
Kadakia et al.
Anticoagulant Use and Bleeding Risk
1172igher CRUSADE bleeding risk score categories were less
ikely to be treated with reperfusion therapy than were those in
he lower CRUSADE bleeding risk score groups (primary
CI: 77.5% vs. 81.7%; fibrinolytics 8.7% vs. 13.1%; no reper-
usion: 13.4% vs. 4.3% in the high CRUSADE bleeding risk
core50 group vs. the low [20] group) (Online Appendix,
nline Table 2).
iscussion
n this large contemporary cohort of patients admitted to
.S. hospitals with myocardial infarction, we find that there
s a wide variability in provider use of anticoagulant regi-
ens with significant differences according to baseline
haracteristics and concomitant therapies. Unfractionated
eparin remains the most commonly used anticoagulant in
urrent practice and is given in over two-thirds of patients
ith STEMI and nearly one-half with NSTEMI. The
ranslation of clinical trial data into clinical practice is
omplex, yet patterns of use of anticoagulants relatively
referred with invasive care among NSTEMI and STEMI
bivalirudin and UFH) and conservative care (LMWH)
mong NSTEMI are discernable. Major bleeding is com-
Table 2. Baseline Characteristics and Concomitant Therapies by Anticoagu
Overall None
Patients, n 72,699 6,420
Baseline characteristics
Age 75 yrs, % 32.5 46.8
Men, % 61.5 55.0
Diabetes mellitus, % 34.1 37.2
Prior vascular disease, % 18.6 22.8
Signs of CHF, % 20.4 28.3
Heart rate, beats/min* 83 (70–98) 85 (72–102)
SBP, mm Hg* 145 (125–166) 141 (119–162)
BMI, kg/m2* 28.4 (24.8–32.7) 27.3 (23.8–31.6)
Baseline hematocrit, %* 41.0 (36.8–44.7) 39.0 (34.5–43.2)
eGFR, ml/min/1.73 m2*† 74.0 (47.7–105.1) 56.9 (35.5–88.3)
eGFR 60 ml/min/1.73 m2, %† 36.5 51.5
Concomitant therapies, %
Clopidogrel‡ 59.1 40.9
75 mg 32.1 49.4
150 mg 1.6 2.0
300 mg 31.1 23.6
600 mg 32.8 22.0
Other 1.0 0.8
GP IIb/IIIa inhibitor 41.2 18.1
Catheterized within 48 h 74.1 58.9
PCI 55.3 29.7
*Continuous variables displayed asmedian valueswith 25th, 75th percentiles.†eGFRdeterminedwi
missing for a small percentage of patients, thus the percentage of distribution by dose does not eq
NSTEMI non–ST-segment elevation myocardial infarction; other abbreviations as in Table 1.on among patients with STEMI and NSTEMI, though a aarge degree of the variability in the rate of bleeding is likely
ased on differences in baseline characteristics and comor-
idities as categorized using the CRUSADE bleeding risk
core and invasive treatment strategies, rather than specific
nticoagulant regimens.
Multiple randomized studies have compared UFH to
MWH, bivalirudin, and fondaparinux, and many have
hown superiority of the latter agents in both STEMI and
STEMI. One exception is the SYNERGY (Superior
ield of the New Strategy of Enoxaparin, Revascularization,
nd Glycoprotein IIb/IIIa Inhibitors) trial, which showed
o difference in ischemic outcomes between UFH and
MWH and increased bleeding with LMWH in a popu-
ation that underwent an early invasive strategy (5). Despite
ost trials showing benefit for agents other than UFH,
FH remains the most commonly used agent in ACS. In
ur analysis, even patients who underwent conservative
trategy (a population different from that of the SYNERGY
rial and 1 in which UFH has not ever been shown to be
uperior), there was significant use of UFH.
Consensus guidelines integrate the results of multiple
rials but are often unable to provide definitive guidance.
hus they give high recommendations for multiple antico-
gent: NSTEMI Patients
UFH LMWH UFH  LMWH Bivalirudin
30,611 19,425 6,957 9,286
28.8 38.3 27.3 26.6
64.3 57.1 62.4 65.4
33.5 34.7 34.3 33.0
18.2 19.7 16.9 16.3
19.1 23.8 19.0 13.4
(70–97) 84 (71–101) 83 (70–98) 80 (69–94)
(125–165) 145 (125–166) 146 (126–165) 148 (129–168)
(25.1–32.7) 28.1 (24.4–32.5) 28.8 (25.2–33.2) 28.9 (25.5–33.1)
(37.1–45.0) 40.5 (36.3–44.2) 41.4 (37.4–45.0) 41.9 (37.8–45.3)
(50.3–107.8) 68.4 (43.9–100.5) 78.4 (52.0–108.2) 81.6 (56.0–111.6)
33.6 41.3 32.2 28.8
62.0 51.2 60.9 76.7
27.9 42.9 29.2 23.8
1.3 2.2 1.7 1.5
32.1 32.0 36.9 27.0
36.4 20.5 29.9 45.6
0.9 1.0 1.1 1.0
51.4 37.3 52.8 23.8
79.1 63.3 76.6 83.7
54.1 35.8 58.1 96.5
roft-Gault formula; dialysis patients excluded fromcalculations.‡Clopidogrel dose informationwas
%.lant A
82
145
28.4
41.4
77.1
th Cock
ual 100gulant strategies and leave open the choice among the 5
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1173vailable agents. Patients in the ACTION registry were
lder and more likely to have comorbidities including
Figure 4. Time Trends in Use of Anticoagulant Regimens in STEMI and NST
Usage of each of the 5 anticoagulant strategies were examined individually in
patients. Trends in use are plotted by anticoagulant strategy. Q  quarter; othiabetes, hypertension, or a prior myocardial infarction than fatients in several of the randomized clinical trials of
nticoagulant strategies (1,2,4,6,8). Thus, physicians may
Patients
quarter from January 2007 to June 2009 for STEMI (A) and NSTEMI (B)
reviations as in Figures 1, 2, and 3.EMI
eacheel the results of these trials are less generalizable to the
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1174verall clinical population and, therefore, may choose UFH,
n agent they are most comfortable using.
Not surprisingly, there was an observed association be-
ween invasive strategies and type of anticoagulant used.
atients undergoing invasive strategies were relatively more
ikely to receive UFH or bivalirudin, due to their easy
itratability and ability to control levels of anticoagulation
uring complicated procedures. LMWH was less frequently
sed in patients undergoing catheterization despite data that
uggest that it is efficacious and safe in this setting (17,18).
MWH was the preferred agent among patients with
STEMI managed with a conservative strategy. Addition-
lly, those receiving bivalirudin or UFH were more likely to
eceive concomitant clopidogrel, also suggesting that these
nticoagulant agents were more commonly used as a part of
n overall treatment strategy that included more potent
ntiplatelet agents and intervention.
When looking at time trends, the increase in bivaliru-
in usage over the last year was notable. This is likely
elated to the publication of the ACUITY (Acute Cath-
terization and Urgent Intervention Triage Strategy
rial) and HORIZONS-AMI (Harmonizing Outcomes
ith Revascularization and Stents in Acute Myocardial
nfarction) trials in November 2006 and May 2008,
espectively.
There were some notable examples of real-world practice
ot supported by clinical evidence. For example, 28.4% of
TEMI patients and 41.3% of NSTEMI patients who
eceived LMWH had estimated glomerular filtration rate
60 ml/min/1.73 m2, even though using LMWH in renal
nsufficiency is associated with an increased risk of
leeding. Another example was patients who receive both
ivalirudin and GP IIb/IIIa inhibitors simultaneously.
Table 3. Distribution of CRUSADE Bleeding Risk Scores and Associated
Bleeding Rates
CRUSADE
Bleeding Score n (%)
Major Bleeding
Events (%)
STEMI, n  42,918
20 19,050 (44.4) 1,036 (5.4)
21–30 9,864 (23.0) 1,002 (10.2)
31–40 6,565 (15.3) 956 (14.6)
41–50 4,250 (9.9) 857 (20.2)
50 3,189 (7.4) 928 (29.1)
NSTEMI, n  61,540
20 19,803 (32.2) 605 (3.1)
21–30 11,134 (18.1) 670 (6.0)
31–40 9,831 (16.0) 822 (8.4)
41–50 8,944 (14.5) 1,099 (12.3)
50 11,828 (19.2) 2,314 (19.6)
CRUSADE  Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Out-
comesWith Early Implementation of ACC/AHA [American College of Cardiology/American Heart
Association] Guidelines; other abbreviations as in Tables 1 and 2.lthough fewer patients on bivalirudin received GP tIb/IIIa inhibitors than those on other anticoagulants, it
as still a sizeable result and not consistent with recent
linical trial data. Additionally, despite the concern
egarding bleeding associated with the crossover between
MWH and UFH in the SYNERGY and ACUITY trials
5,19) and guideline recommendations to avoid “crossing
ver,” between 5% and 10% of patients received both agents
uring their hospitalization. The reason for these practice
atterns is unclear, but the need for further education and
issemination of clinical trial results to all practicing physi-
ians persists.
The GRACE (Global Registry of Acute Coronary Events)
egistry reported anticoagulant use in 12,665 patients admitted
ith ACS between 1999 and 2001, a period almost 8 years
arlier than the cohort evaluated in this analysis (20). Despite
he difference in time and the introduction of bivalirudin, the
se of UFH is essentially identical in patients with STEMI
66.8% in the GRACE registry receiving UFH compared with
6% in the ACTION registry). Comparing the use of
MWH between registries is more complicated because, in
ontrast to the ACTION registry, the GRACE registry
redominately includes non-U.S. sites, in which LMWH is
ore commonly used. However, the use of LMWH in the
CTION registry does appear to have increased from 13%
eported in U.S. sites from the GRACE registry to almost
0% in patients with NSTEMI in the ACTION registry.
A concern in clinical practice is the comparative risk of
ajor bleeding as the result of treatment strategies. We
ound that the risk of bleeding in patients with ACS varies
ignificantly according to baseline characteristics and use of
nvasive strategies, rather than specific anticoagulant regi-
en used. This is an important consideration for clinicians
s concern for bleeding events contributes significantly to
herapeutic decision making during ACS. Thus, a careful
ssessment of the patient’s baseline risk of bleeding relative
o the potential benefit may be more important than
eciding between different anticoagulants.
In our analysis, we both confirm the validity of the
RUSADE bleeding risk score to predict bleeding in
atients with NSTEMI and extend the application of the
leeding score to patients with STEMI in which there is a
lear stepwise increase in bleeding with each higher risk
roup. Interestingly, the overall incidence of bleeding in
ach risk group is higher in STEMI than NSTEMI despite
hat patient population being younger and having fewer
omorbidities. This may be because compared with
STEMI patients, STEMI patients were more univer-
ally managed with cardiac catheterization within 48 h of
rrival (92.0% vs. 74.2% in NSTEMI) and PCI (86.7%
s. 55.3% in NSTEMI), again emphasizing the impor-
ance of invasive strategies in increasing bleeding risk.
dditionally, the CRUSADE bleeding risk score was
eveloped in NSTEMI patients, so it may not fully
ranslate to STEMI patients.
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1175We specifically do not compare the rates of bleeding
etween different anticoagulant treatment regimens be-
ause the large differences in baseline characteristics and
oncomitant therapy between patients receiving different
nticoagulants would bias and confound any true associ-
Figure 5. Distribution of CRUSADE Bleeding Risk Scores by Anticoagulant
Patients were stratiﬁed by anticoagulant strategy and distribution of CRUSADE
NSTEMI. Abbreviations as in Figures 1, 2, 3, and 4.tion in this observational study. Some may find the iower rates of bleeding in patients treated with bivaliru-
in consistent with clinical trial data (2,6). However,
here is a similarly low rate of bleeding in patients treated
ith LMWH, compared with UFH, that is also contrary
o randomized trial results (1). Additionally, there was an
gy in Patients With STEMI and NSTEMI
ing risk score categories was examined in each subgroup: (A) STEMI, and (B)Strate
bleedncreased use of GP IIb/IIIa inhibitors in all groups
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1176elative to the bivalirudin group, possibly increasing
leeding rates in these groups. This highlights the
onfounding that can arise when comparing nonrandom-
zed treatment regimens.
tudy limitations. Limitations of this analysis are that this is
ot a randomized control cohort, and thus associations
etween baseline characteristics, anticoagulant use, and
utcomes is likely to be confounded. Additionally, the
RUSADE bleeding risk score model was developed in
STEMI patients, and, although we apply it to STEMI
atients as well, it is not validated in this group. We could
ot determine the rate of bleeding based on GUSTO
Global Utilization of Streptokinase and Tissue Plasmino-
en Activator for Occluded Coronary Arteries) trial and
IMI (Thrombolysis In Myocardial Infarction) criteria
ecause the ACTION registry does not collect all the
equired criteria for these definitions. However, the
ajor bleeding definition used in the ACTION registry
Figure 6. Rates of Major Bleeding According to Anticoagulation Regime
STEMI and NSTEMI
Patients were ﬁrst divided by anticoagulant strategy. Within each anticoagu
of major bleeding were observed. (A) STEMI; (B) NSTEMI. Abbreviations asas applied similarly to all patients, thus there should be fo significant classification bias between treatment regi-
ens. The data come from hospitals that report to the
CTION registry, and though this does reflect a variety of
ospitals by size, location, private/public, and academic/
onacademic, it does not reflect all hospitals in the U.S.
inally, these data are only from the U.S., and global practice
atterns likely vary.
onclusions
his large, contemporary cohort with myocardial infarc-
ion provides insight into real-world use of anticoagulant
trategies in ACS. There are significant differences in
nticoagulant agent usage, which can be explained by
atient characteristics and concomitant pharmacologic
nd invasive therapies. Use of anticoagulant therapy not
onsistent with clinical guidelines appears to be present
n current practice and, therefore, identifies an important
CRUSADE Bleeding Risk Score Category in Patients With
trategy, patients were divided by CRUSADE bleeding risk score and rates
ures 1, 2, 3, 4, and 5.n and
lant socus for quality improvement programs. Risk of bleeding
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1177an be evaluated using a simple risk score in both
STEMI and STEMI, and across anticoagulant strate-
ies, providing important prognostic information for the
linician. Variability in rates of bleeding is likely based on
ifferences in baseline characteristics, comorbidities, and
nvasive treatment strategies rather than specific antico-
gulation regimens. Future clinical trials perhaps should
lso categorize subjects by bleeding risk (as is already
one for ischemic risk, that is, TIMI and GRACE risk
cores) to understand better any heterogeneity in risk of
leeding for a particular agent. A better understanding of
ow clinicians choose anticoagulant regimens among
vailable recommended options would be important in
mproving the translation of clinical trial data into
eal-world practice.
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